US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Redeye: Orphazyme - Home run moves nearer (and with funding in place)

The case for Orphazyme continues to strengthen as arimoclomol’s US early access program reinforces a raft of positive data and regulatory progress over the past year. The company is now on the verge of starting to harvest its lead project’s USD1bn-plus sales potential, with launch for NPC likely next year in both Europe and the US. Read more and download the latest research report: http://bit.ly/37p0Ay1 Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment

Redeye: Orphazyme - Summary of 2018, important year ahead

Arimoclomol in the NPC indication will drive the story in the near-term but Orphazyme has a broad pipeline with multiple potential value drivers in the longer term. In this update we go through the recent news items and look ahead at the next steps for the company.  Read more and download the latest research report: http://bit.ly/2XBXEu8  Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered

Redeye: Orphazyme - Detailed data shines more light on NPC project

Additional details from the 12-month NPC trial gives a better understanding of arimoclomol in NPC, but there's still uncertainty around the path forward.  Read more and download the initial research report: http://bit.ly/2UuLwsx Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

Redeye: Orphazyme - Top-line data in the NPC Phase II/III shows promise

Top-line data with arimoclomol showed a promising efficacy at 12 months. We believe the results sets up the company for a potential marketing approval if follow-up data is supportive. The data reduces the clinical risk in the project and we raise our Base Case to DKK 122 (110) per share. Read more and download the initial research report: http://bit.ly/2Rhu1ez  Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

Redeye: Orphazyme - Bringing the heat

We initiate coverage of Orphazyme, a Danish pure-play orphan drug company with a late-stage pipeline. Multiple key clinical readouts are lined up for 2018-2021 and lead project arimoclomol could reach the market by 2020. We value the company at DKK 110 in our Base Case, with Bull and Bear Case at DKK 200 and DKK 35 per share, respectively. Read more and download the initial research report: https://goo.gl/2hdxxb Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered

There are no items matching the current filter
There are no more items matching the current filter
Back to top